OnKure Therapeutics FY Conference Summary Company Overview - **Company**: OnKure Therapeutics - **Ticker**: NasdaqGM:OKUR - **Location**: Boulder, Colorado - **Focus**: Development of selective PI3K alpha inhibitors, particularly targeting mutant forms of the enzyme [2][4] Key Product: OKI-219 - **Description**: OKI-219 is the most advanced candidate targeting the PI3K alpha H1047R mutation, which represents approximately two-thirds of mutations in patient populations with mutated PI3K alpha [3][4] - **Selectivity**: OKI-219 exhibits greater than 80-fold selectivity for mutant over wild type PI3K alpha, allowing for effective dosing without significant side effects associated with wild type inhibition [5][7] - **Comparison with Competitors**: Other approved drugs like alpelisib show no selectivity, while inavolisib has only four-fold selectivity. OKI-219's high selectivity minimizes common side effects such as hyperglycemia and rash [6][7] Clinical Studies - **Current Studies**: OKI-219 is involved in three clinical studies: - Monotherapy basket study - Doublet study in combination with fulvestrant for breast cancer - Triplet studies in ER-positive and HER2-positive breast cancer [11][12] - **Data Reporting**: Efficacy data from these studies is expected to be reported in the first quarter of 2026 [13][25] Differentiation and Market Strategy - **Differentiation**: The company aims to differentiate itself by moving into front-line therapy with a well-tolerated regimen, focusing on tolerability and combinability with existing treatments [12][20] - **Target Patient Population**: The HER2-positive breast cancer cohort is noted to have a significant opportunity, despite a lower mutation frequency compared to ER-positive breast cancer [18] CNS Penetration - **Importance**: OKI-219 has a high brain-to-plasma ratio (Kp,uu of 0.6), which is crucial for treating cancers with CNS involvement, particularly HER2-positive breast cancer [15][16] Future Development Plans - **Pan-PI3K Mutant Inhibitor**: The company is also developing a pan-PI3K mutant inhibitor with greater than 10-fold selectivity across all mutants, with plans to report on these developments in the first quarter of 2026 [32] - **Regulatory Strategy**: The company is focused on minimizing risks and ensuring that their drugs do not lead to significant drug-drug interactions (DDIs) with existing therapies [34][35] Conclusion - **Overall Strategy**: OnKure Therapeutics is positioning itself to compete effectively in the oncology market by focusing on high selectivity, tolerability, and strategic partnerships in clinical studies, with a clear timeline for data disclosure and future development [31][32]

Theravance Biopharma Third Quarter 2025 Financial Results and Business Update November 10, 2025 THERAVANCE BIOPHARMA®, THERAVANCE®, the Cross/Star logo and MEDICINES THAT MAKE A DIFFERENCE® are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certain other countries). All third-party trademarks used herein are the property of their respective owners. © 2025 Theravance Biopharma. All rights reserved. Forward Looking Statements Examples of such statements include statement ...

Nasdaq: HIT 22,40,80 30,109,175 210,20,125 This Presentation has been prepared by the Company solely for informational purposes. The information included herein in this presentation has not been independently verified. No representations, warranties or undertakings, express or implied, are made by the Company or any of it' s affiliates, advisers or representatives or the underwriters as to, and no reliance should be placed upon, the accuracy, fairness, completeness or correctness of the information or opini ...

Q3 2025 Financial Performance - Non-GAAP Revenue increased by 21% to $492 million[5, 19] - Adjusted EBITDA declined by 17% to $23.6 million[5, 19] - Non-GAAP EPS decreased by 54% to $0.06[5, 20] - Consumer Services revenue was down 10% to $88.3 million[21] - B2B Services revenue increased by 32% to $364.2 million[21] - Money Movement revenue decreased by 6% to $29.8 million[21] Key Metrics - Active accounts increased by 1%[6, 28] - B2B Services active accounts increased 13% offsetting a 9% decline in Consumer Services active accounts[31] - Gross Dollar Volume (GDV) increased by 18%[29] 2025 Guidance - Projected Non-GAAP Revenue is expected to be between $2 billion and $2.1 billion, representing a 20% growth at the mid-point[61, 62] - Projected Adjusted EBITDA is expected to be between $165 million and $175 million[61] - Projected Non-GAAP EPS is expected to be between $1.31 and $1.44[61]

As a result of these factors, we cannot assure you that the forward-looking statements in this presentation will prove to be accurate. You should understand that it is not possible to predict or identify all such factors. We operate in a competitive and rapidly changing environment. New factors emerge from time to time, and it is not possible to predict the impact of all of these factors on our business, financial condition or results of operations. Furthermore, if our forward-looking statements prove to be ...

Summary of Avalo Therapeutics FY Conference Call Company Overview - **Company**: Avalo Therapeutics (NasdaqCM:AVTX) - **Location**: Near Philadelphia - **New Asset**: AVTX-009, a high affinity human anti-IL-1 beta monoclonal antibody targeting hidradenitis suppurativa (HS) [2][3] Key Points Product Development - **Background**: AVTX-009 was originally developed by Lilly for type 2 diabetes, showing a moderate effect size of 0.25-0.3 grams reduction in hemoglobin A1C, but was not pursued further [2][3] - **Acquisition**: Avalo acquired the asset after it was not advanced by previous owners [3] - **Funding**: The company raised $185 million in 2024 to support its operations and trials [3] - **Lotus Trial**: A phase 2b proof of concept study for AVTX-009 is fully enrolled, with data expected in mid-2026 [4] Mechanism of Action - **IL-1 Beta Role**: IL-1 beta is a master regulator of the immune system, crucial in the inflammatory response in HS lesions [5][6] - **Cytokine Levels**: IL-1 beta is the most abundant cytokine in HS lesions, making it a prime target for treatment [7] Comparison with Competitors - **AbbVie’s Lutikizumab**: A bispecific anti-IL-1 beta and anti-IL-1 alpha drug with a shorter half-life and lower affinity for IL-1 beta compared to AVTX-009 [11][12] - **Efficacy Data**: AbbVie reported a drug effect size of approximately 46% in a severe HS population, which Avalo aims to exceed with its higher affinity drug [13][15] Trial Design and Expectations - **Placebo Response**: The Lotus trial is designed to mitigate placebo responses, with a conservative estimate of a 20% placebo rate based on historical data [19][20] - **Patient Demographics**: The trial includes a mix of biologically experienced patients, with a higher proportion of TNF and IL-17 failures compared to competitors [25][26] Future Indications - **Exploration Beyond HS**: Avalo is interested in expanding indications to include crystal arthropathies, such as gout, in addition to other inflammatory conditions [30][31] Financial Health - **Balance Sheet**: Avalo has $115 million available, sufficient to fund operations through data release and into 2028, with plans to raise funds for phase three trials [33] Additional Insights - **Trial Management**: The company emphasizes rigorous training for investigators to ensure objective assessments and accurate data collection [27][28] - **Statistical Approach**: Avalo plans to handle non-responder imputation scientifically, contrasting with other companies' methods that may artificially lower efficacy results [29]

Financial Performance - 3Q25 revenue reached $60.2 million, exceeding the high-end of the guidance range of $56 million to $59 million[8] - Adjusted EBITDA for 3Q25 was $4.8 million, also surpassing the high-end of the guidance range of $(4) million to $(2) million[8] - Recurring revenue accounted for 92% of total revenue in 3Q25, amounting to $55.1 million[8] - The company anticipates adjusted EBITDA to exceed Capex in FY25[8] Customer Metrics - The average revenue per customer (ARPC) increased to $665,000 in 3Q25[16] - Net revenue retention rate for recurring revenue was 78% in 3Q25[16] - Remaining performance obligations stood at $197 million in 3Q25[16] Guidance - 4Q25 revenue is projected to be between $50.5 million and $55.5 million, representing a year-over-year decline of (31)% to (24)%[19] - Full year 2025 revenue is guided to be in the range of $235 million to $240 million, a year-over-year decrease of (25)% to (23)%[19] - Adjusted EBITDA for 4Q25 is expected to be between $(0.3) million and $4.7 million, with a margin of (0.6)% to 8.5%[19] - Full year 2025 adjusted EBITDA is projected to be between $7.5 million and $12.5 million, with a margin of 3.2% to 5.2%[19]

THIRD QUARTER 2025 BUSINESS UPDATE This communication contains "forward-looking statements" that are not historical facts, and involve risks and uncertainties that could cause actual results of AST SpaceMobile to differ materially from those expected and projected. These forward-looking statements can be identified by the use of forward-looking terminology, including the words "believes," "estimates," "anticipates," "expects," "intends," "plans," "may," "will," "would," "potential," "projects," "predicts," ...

3Q 2025 Earnings Presentation November 2025 FORWARD- LOOKING STATEMENTS Statements made in this presentation regarding American Public Education, Inc. or its subsidiary institutions ("APEI" or the "Company") that are not historical facts are forward-looking statements based on current expectations, assumptions, estimates and projections about APEI and the industry. In some cases, forward looking statements can be identified by words such as "anticipate," "believe," "seek," "could," "estimate," "expect," "in ...

Financial Performance - Q3 2025 revenue reached $123.3 million, a 21.6% year-over-year increase[16] - Q3 2025 gross margin improved to 37.6%, a 4.4 percentage point increase year-over-year[16] - Q3 2025 adjusted net profit was $11.9 million[18,50] - Q3 2025 adjusted EBITDA was $21.9 million[20,50] - The company ended the period with $143 million in cash, including restricted cash, a $33 million increase[59] Business Development and Strategy - The company established a partnership with Škoda Group to develop battery systems for rail applications, with the first prototype expected by the end of 2026[44] - The company is expanding its Huzhou facility with Phase 3.2, expected to provide an additional 2 GWh of capacity annually, with initial production anticipated in Q1 2026[28,33] - The company is focused on product innovation, market capture, and capacity expansion[23,24] Outlook - The company projects revenue growth of 18-25% for 2025, with revenue guidance of $450-475 million[63,64] - The company is targeting a gross margin range of 32%-35% for 2025[65] - The company anticipates over 50% year-over-year revenue growth in the Americas for 2025[67]